EKF Diagnostics Holdings plc (LON:EKF - Get Free Report)'s stock price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 23.83 ($0.32) and traded as high as GBX 25.90 ($0.35). EKF Diagnostics shares last traded at GBX 25.90 ($0.35), with a volume of 20,041 shares changing hands.
EKF Diagnostics Stock Performance
The stock's 50-day moving average is GBX 23.77 and its 200-day moving average is GBX 23.86. The firm has a market capitalization of £117.78 million, a price-to-earnings ratio of 24.66 and a beta of 0.57. The company has a current ratio of 4.60, a quick ratio of 1.77 and a debt-to-equity ratio of 0.34.
EKF Diagnostics (LON:EKF - Get Free Report) last issued its quarterly earnings data on Tuesday, March 25th. The company reported GBX 1.38 ($0.02) earnings per share for the quarter. EKF Diagnostics had a net margin of 9.37% and a return on equity of 7.03%. On average, analysts predict that EKF Diagnostics Holdings plc will post 2.2987842 EPS for the current fiscal year.
Insider Activity
In other news, insider Gavin T. Jones purchased 50,000 shares of the company's stock in a transaction that occurred on Tuesday, March 25th. The shares were acquired at an average cost of GBX 22 ($0.30) per share, with a total value of £11,000 ($14,792.90). 5.24% of the stock is owned by company insiders.
EKF Diagnostics Company Profile
(
Get Free Report)
EKF is an AIM-listed global diagnostics business focussed on:
● Point-of-Care analysers in the key areas of Hematology and Diabetes
● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
Further Reading
Before you consider EKF Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EKF Diagnostics wasn't on the list.
While EKF Diagnostics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
